ArticleBMC rheumatology2022
Predictive value of erythrocyte sedimentation rate and C-reactive protein in Behcet's disease activity and manifestations: a cross-sectional study.
Article in BMC rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Unmasking Behçet's disease in the European population: a case series report.Rheumatology international · 2026Article
- Real-World Distributions and Concordance of C-Reactive Protein and Erythrocyte Sedimentation Rate Across Rheumatic Diseases.Clinics and practice · 2026Article
- Artificial intelligence in immunotherapy: revolutionizing diagnostic and therapeutic applications in cancer and autoimmune diseases.Clinical and experimental medicine · 2026Review
- The Role of HLA-B Typing in Behçet's Disease and Spondyloarthritis: Genetic and Clinical Insights.Life (Basel, Switzerland) · 2026Article
- Fatal Aortic Regurgitation in Behçet's Disease: A Case Report Highlighting Pitfalls and Lessons in Preoperative DiagnosisCurrent medical imaging · 2026Article
- Intracardiac Thrombi in Behçet's Disease: Systematic Review of 218 Patients' Clinical Characteristics and Treatments.European cardiology · 2026Review
- Systemic Immune-Inflammation Index as a Marker of Activity in Behcet's Uveitis.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026Article
- Evaluation of predictors and clinical outcome after tapering of chronic systemic corticosteroids in Behçet's disease patients.Clinical rheumatology · 2026Observational
- Exosomes in Clinical Laboratory: From Biomarker Discovery to Diagnostic Implementation.Medicina (Kaunas, Lithuania) · 2025Review
- Identification of markers predicting clinical course in patients with Behcet disease by combination of machine learning and unbiased clustering analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Clinical Characteristics, MRI Findings, Disease Progression, and Management of Neuro-Behçet's Disease: A Retrospective Study in Lebanon.Journal of clinical medicine · 2025Article
- Characterization of potential salivary biomarkers in Behçet's disease.Internal and emergency medicine · 2025Article
- Novel inflammatory biomarkers for discriminating vascular involvement in Behçet's syndrome: evaluating SII, SIRI, and NPAR.Biomarkers in medicine · 2025Article
- Relationship between C-reactive protein/albumin ratio and mucocutaneous symptom frequency and disease severity in Behçet's disease.Turkish journal of medical sciences · 2024Article
- C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.Diseases (Basel, Switzerland) · 2023Review
- Oral Lesions as the Primary Manifestations of Behçet's Disease: The Importance of Interdisciplinary Diagnostics-A Case Report.Biomedicines · 2023Article
- Serum Elafin as a Potential Marker of Disease Activity in Behçet's Disease.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBehcet's disease (BD) as a chronic inflammatory condition that affects the eyes, skin, central nervous system, gastrointestinal tract and vessels. According to the literature, the exact value of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in predicting active manifestations of BD remains controversial. In this study, we aim to assess and compare values of ESR and CRP between BD patients with active/inactive BD and active/inactive manifestations of the disease. Moreover, we try to determine the predictive value of ESR and CRP for disease activity.
methodsParticipants (n = 514) were drug-naïve BD patients; Based on last two visits, ESR and CRP values, disease activity, and active manifestations were recorded. The Man-Whitney U test measured the associations, and the binomial logistic regression evaluated the predictive value of ESR and CRP for active disease and each active manifestation. The sensitivity and specificity and the area under the curve (AUC) for each model were determined using receiver operating characteristic curves (ROC). Multiple regressions were run to predict BD activity score from ESR and CRP.
resultPatients with active oral, genital, joint and dermal manifestations had higher ESR and CRP values (Mann-Whitney U test, p < 0.05 for all). Binomial logistic regressions showed that ESR had valuable predictive value for active BD (OR = 1.09 [1.04-1.13], AUC = 0.79 [0.74-0.83], p < 0.001) and active vascular manifestations (1.03 [1.01-1.05], AUC = 0.85 [0.79-0.92], p < 0.001). CRP had good predictive value for active vascular manifestations (OR 1.98 [1.45-2.72], AUC = 0.86 [0.8-0.91], p < 0.001). The optimal value of ESR ≥ 10.5 and ESR ≥ 42.5 could predict active BD and active vascular manifestations with sensitivity, specificity = 71%, 75% and = 81%, 83% respectively.
conclusionsESR and CRP are both associated with active BD and most manifestations of the diseases. They can be used for the prediction of active BD and active vascular manifestations in BD patients. Further studies can help to confirm the findings of the current research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.